lemborexant sold brand name dayvigo orexin antagonist medication used treatment indicated specifically treatment insomnia characterized difficulties sleep onset andor maintenance medication taken side effects lemborexant include somnolence fatigue headache abnormal medication dual orexin receptor antagonist acts selective dual antagonist orexin receptors lemborexant long elimination halflife hours time peak benzodiazepine zdrug interact gaba receptors instead distinct mechanism lemborexant approved medical use united states december schedule iv controlled substance united states may low potential besides lemborexant orexin receptor antagonists including suvorexant daridorexant also lemborexant used treatment insomnia major systematic review network metaanalysis medications treatment insomnia published found lemborexant effect size standardized mean difference smd placebo treatment insomnia weeks citooltip confidence interval months ci lemborexant similar effect sizes weeks evaluated marketed orexin receptor antagonists suvorexant smd ci daridorexant smd ci whereas benzodiazepines zdrugs generally showed larger effect sizes eg smds lemborexant orexin receptor however review concluded lemborexant eszopiclone among insomnia medications assessed best profiles overall terms efficacy tolerability compared benzodiazepines low risk developing tolerance memory attention affected next morning taking lemborexant available form mg oral filmcoated side effects lemborexant include somnolence fatigue combined preferred terms somnolence lethargy fatigue sluggishness mg mg vs placebo headache mg mg vs placebo nightmares abnormal dreams mg mg vs less common side effects include sleep paralysis mg mg vs placebo hypnagogic hallucinations mg mg vs lemborexant doses mg produces drugliking responses similar zolpidem mg suvorexant mg recreational sedative drug controlled substance united states considered low misuse lemborexant dual antagonist orexin associates dissociates orexin receptors rapidly certain orexin receptor antagonists suvorexant may cause shorter duration bioavailability lemborexant good least time peak levels lemborexant highfat highcalorie meal found delay time peak levels plasma protein binding vitro lemborexant metabolized primarily lesser extent effective halflife lemborexant hours terminal elimination halflife medication excreted feces lesser extent urine although lemborexant longer terminal elimination halflife suvorexant appears rapidly cleared suvorexant earlier phases addition lemborexant dissociates orexin receptors rapidly differences may allow comparatively reduced nextday effects daytime somnolence june eisai initiated phase iii clinical trials united states france germany italy japan poland spain december lemborexant approved use united states based results sunrise sunrise phase iii clinical lemborexant generic name drug inntooltip international nonproprietary name developmental code name lemborexant sold brand name lemborexant marketed united states canada australia approved european medicines agency ema use european union medicines healthcare products regulatory agency mhra united lemborexant development treatment circadian rhythm sleep disorders sleep apnea chronic obstructive pulmonary february phase clinical trials circadian rhythm sleep disorders phase trials sleep apnea chronic obstructive pulmonary httpsenwikipediaorgwikilemborexant